Alternating regimens

Some researchers have proposed strategies whereby patients alternate or cycle back and forth between two or more different antiretroviral drug regimens. This is based on the theory that regularly switching drugs might reduce the length of time a person is exposed to a failing regimen, thereby minimising the emergence of drug resistance.

The SWATCH study, for example, found that patients who alternated between AZT/3TC/nelfinavir and d4T/ddI/efavirenz experienced treatment failure later than those who stayed on a single regimen.1 However, other research has not been as promising, and this strategy has largely fallen out of favour.

References

  1. Martinez-Picado J et al. Alternation of anti-HIV drug regimens for HIV infection: A randomized, controlled trial. Ann Intern Med 139: 81-89, 2003
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.